adminmain, Author at Dermaxon

Dermaxon receives grant from the National Institute of Neurological Disorders and Stroke

September 2019: DermaXon received a Phase 1 STTR Grant funding from the National Institute of Neurological Disorders and Stroke to support preclinical efficacy studies for a novel drug treatment for pruritus. This award, titled “TOPICAL SELECTIVE T-TYPE BLOCKERS FOR...

DermaXon LLC awarded grant for continued development of DX308 drug candidate for the treatment of Ichthyosis

MiSSOULA, Montana, Nov. 20, 2018 – DermaXon was been awarded a research grant from The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to further research treatment options for Ichthyosis.

Characterization of CYP26B1-selective Inhibitor, DX314, as a Potential Therapeutic for Keratinization Disorders.

Background: Retinoid-based therapies are commonly used in the treatment of disorders of keratinization and other skin disorders but can result in non-specific effects and adverse reactions. Use of retinoic acid metabolism blocking agents (RAMBAs) such as DX308 may...

Dermaxon receives grant from the National Institute of Neurological Disorders and Stroke

June 2018: DermaXon received a Phase 1 STTR Grant funding from the National Institute of Neurological Disorders and Stroke to support preclinical efficacy studies for a novel drug treatment for pain. This award titled “Topical selective T-type blockers for the...

Upcoming Conferences

March, 2020: American Academy of Dermatology (AAD) Annual Meeting (Denver, CO, USA) Poster title: Computational Docking Studies of Natural AKR1B10 inhibitors to Improve Retinaldehyde Efficacy and Increase Endogenous atRA Synopsis: Using molecular docking and...